HB1683

Oklahoma HB1683 mandates reimbursement for a twelve-month supply of FDA-approved contraceptive drugs under health benefit plans.

Oklahoma HB1683 requires health benefit plans to reimburse enrollees for a twelve-month supply of FDA-approved contraceptive drugs, including hormonal drugs administered orally, transdermally, and intravaginally. This applies each time the enrollee obtains the same drug, regardless of their enrollment status. The bill defines "contraceptive drugs" and "health benefit plan," and specifies that nothing in the act requires coverage for drugs not intended for regular or routine use. The act becomes effective November 1, 2025.